Trials / Completed
CompletedNCT01836146
International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this First-in-Human Clinical investigation is to evaluate the safety and performance of the St. Jude Medical EnligHTN™ Generation 2 Renal Denervation System for the treatment of patients with drug-resistant uncontrolled hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | EnligHTN™ Renal Artery Ablation Catheter |
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-03-01
- Completion
- 2015-09-01
- First posted
- 2013-04-19
- Last updated
- 2019-02-04
Locations
6 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT01836146. Inclusion in this directory is not an endorsement.